| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.028 | 0.5 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | 0.036 | 0.5 |
| mRNA | blebbistatin | CTRPv2 | pan-cancer | AAC | -0.055 | 0.5 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | 0.053 | 0.5 |
| mRNA | JW-55 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.5 |
| mRNA | BMS-754807 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | 0.027 | 0.5 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.026 | 0.5 |